SCM
NBIX icon

Silverarc Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Silverarc Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-162,969
Closed -$20.5M – 90
2025
Q2 		$20.5M Buy
162,969
+90,386
+125% +$10.4M 3.78% 8
2025
Q1 		$8.03M Buy
+72,583
New +$9.19M 1.64% 19
2022
Q2 		– Sell
-20,482
Closed -$1.92M – 80
2022
Q1 		$1.92M Buy
+20,482
New +$1.74M 0.79% 31

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Silverarc Capital Management's NBIX Position: Q3 2025 in Review

Silverarc Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 162,969 shares — an estimated $20.5M sold.

Silverarc Capital Management first reported a position in NBIX in Q1 2022 and held it in 3 quarters. The position peaked at $20.5M in Q2 2025. 650 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Silverarc Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Silverarc Capital Management sold 162,969 Neurocrine Biosciences shares in Q3 2025, an estimated $20.5M.
  • Silverarc Capital Management first reported a position in Neurocrine Biosciences in Q1 2022 and held it in 3 quarters.
  • Silverarc Capital Management's Neurocrine Biosciences position peaked at $20.5M in Q2 2025.
  • 650 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Silverarc Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.